Vertex Completes $10 Billion Crinetics Acquisition at $85 a Share

Vertex Pharmaceuticals completed its acquisition of Crinetics Pharmaceuticals on September 1, closing a cash buyout that was announced in July at $85 a share. The deal gives Vertex a marketed endocrine medicine, a Phase 3 rare-disease program and a broader set of earlier pipeline assets that management says can add to revenue growth and support its long-term earnings profile.

The purchase was framed from the start as a way for Vertex to add assets outside its core cystic fibrosis franchise while staying in serious diseases and specialty markets where it already likes to operate. Crinetics fits that template closely. Its commercial product PALSONIFY is already on the market in the United States for acromegaly, and its lead pipeline candidate atumelnant is further along than many development-stage programs that change hands in large biotechnology acquisitions.

In its September 1 closing announcement, Vertex said the acquisition was completed after the necessary regulatory clearances and approval by Crinetics shareholders. The company also said it will discuss the accounting and financial effects of the purchase on its third-quarter earnings call, which is scheduled for November 2.

Cash merger closes on the July terms

The economics of the acquisition did not change at closing. When Vertex announced the agreement on July 6, it said it would pay $85.00 in cash for each Crinetics share, valuing the company at about $10.0 billion on an equity basis, or about $8.8 billion net of estimated cash acquired. Vertex repeated those figures in the September 1 completion release, so the basic terms that investors evaluated in July remained intact through closing.

That matters because the deal was struck as a fixed-cash purchase rather than a share exchange. Crinetics holders receive a set dollar amount rather than a value that moves with Vertex’s share price. For Vertex, the attraction was not financial engineering but the chance to bring in assets it believes can broaden the company’s growth base. For Crinetics investors, the buyout delivered certainty of value at the agreed price once the remaining conditions were cleared.

The acquisition also moved quickly by large-biotech standards. Vertex signed the merger agreement on July 6 and completed the purchase on September 1, a span of less than two months. During that period, the companies moved through the required approval steps and then closed without changing the headline price or publicly revising the strategic case laid out when the agreement was signed.

Alongside the completion notice, Vertex announced management changes tied to its next phase of growth. Charles Wagner, previously executive vice president and chief operating and financial officer, is taking on an expanded chief operating officer role with responsibility for overseeing the integration of Crinetics, effective immediately. Vertex also said Jonathan Poole is set to become chief financial officer on January 1, 2027, while Wagner continues as chief operating officer.

PALSONIFY and atumelnant are the core strategic prize

The acquisition brings in assets with different time horizons. PALSONIFY, the brand name for paltusotine, is already contributing commercial revenue. Vertex described it as the first and only once-daily oral therapy for acromegaly, and said it has been launched in the United States, approved in the European Union and is under review in other markets. That gives Vertex an immediate commercial foothold in endocrine disease rather than forcing it to wait for the first product launch.

Atumelnant is the more developmental part of the story, but it is also a large part of the financial upside management is pointing to. Vertex said the drug candidate is in Phase 3 development for congenital adrenal hyperplasia and in Phase 2 development for Cushing’s syndrome. Those are still clinical programs, not approved products, so any revenue contribution depends on successful trial execution and future regulatory decisions. Even so, Vertex is clearly treating atumelnant as a late-stage asset with meaningful commercial potential.

Management’s most ambitious claim is its forecast that PALSONIFY and atumelnant together can eventually generate more than $5 billion in combined annual revenue at peak. That is a company projection, not an externally verified outcome, and it depends on launch execution, reimbursement, physician adoption, competition and the remaining clinical and regulatory milestones. Still, the scale of that estimate helps explain why Vertex was willing to commit $10 billion of equity value to the acquisition.

The broader fit is also important. Vertex already sells therapies in cystic fibrosis and has expanded into areas including sickle cell disease, beta thalassemia and acute pain. Crinetics gives the company a deeper position in endocrinology with one launched medicine and additional programs behind it. In that sense, the acquisition is less about a single product and more about adding another disease-area platform that Vertex believes can compound over time.

Focus shifts to financing, integration and November disclosures

When the companies unveiled the agreement in July, Vertex said it expected to finance the purchase with a combination of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing from Bank of America and Morgan Stanley Senior Funding. The September 1 release did not announce a different funding structure, so the market’s starting assumption remains that Vertex used the mix outlined when the merger was signed, even if the final funding mechanics will become clearer in later filings and earnings materials.

Vertex also kept its profitability message in place. The company again said the Crinetics purchase is expected to become accretive to non-GAAP operating income in 2029. That timeline is still several years away and should be read as management guidance rather than a guaranteed outcome. The expected lift depends on the pace of PALSONIFY’s commercial uptake, the progress of atumelnant through development, the cost of integration and the ultimate financing burden associated with the deal.

Integration now becomes the practical test of the acquisition case. Vertex paired the closing news with the decision to put Wagner in charge of integrating Crinetics, signaling that the company wants the handoff from signing to execution to happen quickly. Integration in biotechnology is often less about overlapping factories or broad cost cuts than about keeping development programs on track, maintaining commercial momentum and retaining scientific talent that is central to future value creation.

The next concrete checkpoint is November 2, when Vertex says it will provide details on the accounting and financial effects of the acquisition during its third-quarter earnings call. That disclosure should give investors a clearer view of purchase accounting, any near-term earnings impact and how Vertex expects Crinetics to show up in its financial statements after the first month of ownership.